An Observational Study of YUTIQ (Fluocinolone Acetonide Intravitreal Implant 0.18 mg) for the Management of Chronic Non-infectious Uveitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This project is designed to evaluate the efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious uveitis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
View:
• Male or female in good general health at 18 to 70 years of age.
• Presence of unilateral or bilateral non-infectious uveitis affecting the posterior segment
• Patients have active inflammation before Yutiq treatment. Subject meets at least 1 of the following criteria: 1. ≥1+ anterior chamber cell and/or ≥1+ vitreous haze. 2. Fluorescein angiography demonstrates leakages. 3. OCT images showing the macular edema. 4. The times of relapse in one year are equal to or greater than 3.
• Steroids and immunosuppressive agents were discontinued within 3 months after Yutiq injection.
Locations
Other Locations
China
Tianjin Medical University Eye Hospital
RECRUITING
Tianjin
Contact Information
Primary
xiaomin Zhang
xiaomzh@126.com
+8613920023990
Time Frame
Start Date: 2023-01-05
Estimated Completion Date: 2026-11-01
Participants
Target number of participants: 15
Treatments
Yutiq group
Patients will receive YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye and will be followed for 36 months after treatment.
traditional therapy group
Patients were treated with glucocorticoids alone or glucocorticoids combined with immunosuppressants and were followed for up to 36 months.
Related Therapeutic Areas
Sponsors
Leads: Tianjin Medical University